Baker Bros. Advisors as of Dec. 31, 2025
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 86 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | 17.8 | $3.0B | 31M | 98.77 | |
| BeOne Medicines Sponsored Ads (ONC) | 15.7 | $2.7B | 8.8M | 303.81 | |
| Madrigal Pharmaceuticals (MDGL) | 7.3 | $1.2B | 2.1M | 582.34 | |
| Insmed Incorporated Com Par $.01 (INSM) | 6.7 | $1.1B | 6.6M | 174.04 | |
| ACADIA Pharmaceuticals (ACAD) | 6.7 | $1.1B | 43M | 26.71 | |
| Celcuity (CELC) | 4.6 | $790M | 7.9M | 99.74 | |
| Revolution Medicines (RVMD) | 4.4 | $753M | 9.5M | 79.65 | |
| Kymera Therapeutics (KYMR) | 3.9 | $674M | 8.7M | 77.81 | |
| Summit Therapeutics (SMMT) | 3.7 | $637M | 36M | 17.49 | |
| Rhythm Pharmaceuticals (RYTM) | 3.5 | $600M | 5.6M | 107.04 | |
| Kodiak Sciences (KOD) | 3.3 | $557M | 20M | 27.96 | |
| Praxis Precision Medicines I (PRAX) | 1.9 | $332M | 1.1M | 294.74 | |
| Alkermes SHS (ALKS) | 1.6 | $280M | 10M | 27.98 | |
| Grail (GRAL) | 1.0 | $179M | 2.1M | 85.59 | |
| Edgewise Therapeutics (EWTX) | 1.0 | $163M | 6.6M | 24.82 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.8 | $144M | 2.2M | 66.39 | |
| Ionis Pharmaceuticals (IONS) | 0.8 | $142M | 1.8M | 79.11 | |
| Immunovant (IMVT) | 0.8 | $139M | 5.5M | 25.42 | |
| Immatics SHS (IMTX) | 0.7 | $127M | 12M | 10.50 | |
| Ideaya Biosciences (IDYA) | 0.7 | $125M | 3.6M | 34.57 | |
| Roivant Sciences SHS (ROIV) | 0.7 | $121M | 5.6M | 21.70 | |
| Abivax Sponsored Ads (ABVX) | 0.7 | $118M | 876k | 134.85 | |
| Kiniksa Pharmaceuticals International Ord Shs Cl A (KNSA) | 0.7 | $117M | 2.8M | 41.25 | |
| Replimune Group (REPL) | 0.6 | $107M | 11M | 9.72 | |
| Stoke Therapeutics (STOK) | 0.6 | $106M | 3.3M | 31.74 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 0.6 | $100M | 1.4M | 69.55 | |
| Abcellera Biologics (ABCL) | 0.6 | $94M | 28M | 3.42 | |
| Nurix Therapeutics (NRIX) | 0.5 | $88M | 4.7M | 18.97 | |
| Immunocore Holdings Ads (IMCR) | 0.5 | $81M | 2.3M | 34.71 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.5 | $77M | 11M | 7.08 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.4 | $77M | 1.6M | 46.55 | |
| Monte Rosa Therapeutics (GLUE) | 0.4 | $68M | 4.3M | 15.68 | |
| Celcuity Note 2.75% 8/1/2031 (Principal) | 0.4 | $67M | 31M | 2.17 | |
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $64M | 2.8M | 23.00 | |
| Denali Therapeutics (DNLI) | 0.4 | $62M | 3.7M | 16.51 | |
| Miragen Therapeutics (VRDN) | 0.4 | $61M | 2.0M | 31.12 | |
| Entrada Therapeutics (TRDA) | 0.3 | $52M | 5.1M | 10.28 | |
| Rapport Therapeutics (RAPP) | 0.3 | $47M | 1.5M | 30.34 | |
| Terns Pharmaceuticals (TERN) | 0.2 | $38M | 950k | 40.40 | |
| BioNTech SE Sponsored Ads (BNTX) | 0.2 | $35M | 369k | 95.20 | |
| Aeglea Biotherapeutics (SYRE) | 0.2 | $33M | 1.0M | 32.76 | |
| Dianthus Therapeutics (DNTH) | 0.2 | $33M | 790k | 41.21 | |
| Prelude Therapeutics (PRLD) | 0.2 | $29M | 10M | 2.90 | |
| DBV Technologies Sponsored Ads (DBVT) | 0.2 | $28M | 1.5M | 19.17 | |
| Disc Medicine (IRON) | 0.2 | $27M | 337k | 79.41 | |
| Jade Biosciences (JBIO) | 0.1 | $25M | 1.6M | 15.43 | |
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $22M | 4.0M | 5.50 | |
| BioCryst Pharmaceuticals (BCRX) | 0.1 | $22M | 2.8M | 7.80 | |
| Ventyx Biosciences (VTYX) | 0.1 | $21M | 2.3M | 9.03 | |
| argenx SE Sponsored Adr (ARGX) | 0.1 | $21M | 25k | 840.95 | |
| Design Therapeutics (DSGN) | 0.1 | $21M | 2.2M | 9.38 | |
| Cerus Corporation (CERS) | 0.1 | $21M | 10M | 2.06 | |
| Neurogene (NGNE) | 0.1 | $20M | 992k | 20.60 | |
| Tectonic Therapeutic (TECX) | 0.1 | $19M | 903k | 20.86 | |
| Cytomx Therapeutics (CTMX) | 0.1 | $18M | 4.3M | 4.26 | |
| Celldex Therapeutics (CLDX) | 0.1 | $18M | 665k | 27.16 | |
| Xencor (XNCR) | 0.1 | $17M | 1.1M | 15.31 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $17M | 671k | 25.01 | |
| Xenon Pharmaceuticals (XENE) | 0.1 | $17M | 370k | 44.82 | |
| Sionna Therapeutics (SION) | 0.1 | $17M | 400k | 41.14 | |
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $16M | 1.4M | 11.43 | |
| Sera Prognostics Class A Com (SERA) | 0.1 | $16M | 5.5M | 2.95 | |
| Dyne Therapeutics (DYN) | 0.1 | $16M | 813k | 19.56 | |
| Alumis (ALMS) | 0.1 | $15M | 1.6M | 9.76 | |
| Nuvalent Inc-a (NUVL) | 0.1 | $15M | 144k | 100.59 | |
| Pharvaris N V (PHVS) | 0.1 | $10M | 375k | 27.75 | |
| Relay Therapeutics (RLAY) | 0.1 | $9.8M | 1.2M | 8.46 | |
| Absci Corp (ABSI) | 0.0 | $7.5M | 2.1M | 3.49 | |
| Arcus Biosciences Incorporated (RCUS) | 0.0 | $6.4M | 270k | 23.83 | |
| Maplight Therapeutics (MPLT) | 0.0 | $6.4M | 365k | 17.57 | |
| vTv Therapeutics Cl A (VTVT) | 0.0 | $5.9M | 148k | 39.99 | |
| Wave Life Sciences SHS (WVE) | 0.0 | $5.8M | 344k | 17.00 | |
| Sagimet Biosciences Com Ser A (SGMT) | 0.0 | $5.6M | 953k | 5.92 | |
| Protara Therapeutics Com Stk (TARA) | 0.0 | $5.2M | 972k | 5.33 | |
| LB Pharmaceuticals Com Shs (LBRX) | 0.0 | $4.5M | 200k | 22.26 | |
| Enliven Therapeutics (ELVN) | 0.0 | $4.2M | 271k | 15.40 | |
| 4d Molecular Therapeutics In (FDMT) | 0.0 | $3.6M | 476k | 7.50 | |
| Vir Biotechnology (VIR) | 0.0 | $3.3M | 543k | 6.03 | |
| Tscan Therapeutics (TCRX) | 0.0 | $2.8M | 2.8M | 1.00 | |
| Sana Biotechnology (SANA) | 0.0 | $1.3M | 311k | 4.07 | |
| Skye Bioscience (SKYE) | 0.0 | $1.1M | 1.5M | 0.75 | |
| Kala Pharmaceuticals (KALA) | 0.0 | $1.0M | 1.8M | 0.56 | |
| Aligos Therapeutics (ALGS) | 0.0 | $774k | 83k | 9.32 | |
| Tyra Biosciences (TYRA) | 0.0 | $279k | 11k | 26.29 | |
| Acrivon Therapeutics Common Stock (ACRV) | 0.0 | $55k | 23k | 2.41 | |
| Surrozen W Exp 8/11/2026 (SRZNW) | 0.0 | $17k | 833k | 0.02 |
